会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明授权
    • Pharmaceutically active benzoquinazoline compounds
    • 药用活性苯并喹唑啉化合物
    • US06306865B1
    • 2001-10-23
    • US09588790
    • 2000-06-06
    • William PendergastScott Howard DickersonJulius Vass JohnsonRobert Ferone
    • William PendergastScott Howard DickersonJulius Vass JohnsonRobert Ferone
    • C07D23970
    • C07D403/12C07D239/70C07D239/88C07D417/12
    • Compounds of formula (I) or salts thereof, wherein the dotted line represents a single or double bond, R1 is alkyl or amino optionally substituted by alkyl, alkanoyl or benzyl group; R2, R3, R4 and R5 are the same or different and each is selected from hydrogen, phenyl, halo, nitro, a group S(O)nR8 wherein n is the integer 0, 1 or 2 and R8 is halo or alkyl or a group NR9R10 wherein R9 and R10 are both hydrogen, a group NR11R12 wherein R11 and R12 are the same or different and each is hydrogen or alkyl, a group OR13 wherein R13 is hydrogen or C1-4 of alkyl optionally substituted by halo; a C1-4 aliphatic group optionally substituted by a group OR14 or NR14R15 wherein R14 and R15 are the same or different and each is hydrogen or alkyl; or two of R2 to R5 are linked together to form a benzo group, or one of R2 to R5 is a group X—Y—R16 wherein X is CH2, NR17, CO or S(O)m and Y is CH2, NR17, O or S(O)m, or X—Y is O, NR17, —CH═CH— or N═N—, are disclosed as pharmacological agents useful in the treatment of tumours. Pharmaceutical compositions and methods for the preparation of compounds of formula (I) are also described.
    • 式(I)化合物或其盐,其中虚线表示单键或双键,R1是任选被烷基,烷酰基或苄基取代的烷基或氨基; R 2,R 3,R 4和R 5相同或不同,各自选自氢,苯基,卤素,硝基,基团S(O)n R 8,其中n为整数0,1或2,且R 8为卤素或烷基或 NR 9 R 10基团,其中R 9和R 10均为氢,NR 11 R 12基团,其中R 11和R 12相同或不同,各自为氢或烷基,OR 13,其中R 13为氢或任选被卤素取代的烷基的C 1-4; 任选被OR 14或NR 14 R 15基团取代的C 1-4脂族基团,其中R 14和R 15相同或不同,各自为氢或烷基; 或R 2至R 5中的两个连接在一起形成苯并基团,或者R 2至R 5中的一个为XY-R 16基团,其中X为CH 2,NR 17,CO或S(O)m,Y为CH 2,NR 17,O或 公开了S(O)m或XY为O,NR 17,-CH = CH-或N = N-作为可用于治疗肿瘤的药理学试剂。 还描述了制备式(I)化合物的药物组合物和方法。
    • 23. 发明授权
    • Pharmaceutically active benzoquinazoline compounds
    • 药用活性苯并喹唑啉化合物
    • US6090941A
    • 2000-07-18
    • US956018
    • 1993-01-13
    • William PendergastScott Howard DickersonJulius Vass JohnsonRobert Ferone
    • William PendergastScott Howard DickersonJulius Vass JohnsonRobert Ferone
    • A61K31/505A61K31/00A61K31/50A61K31/501A61K31/517A61P31/00A61P31/04A61P35/00A61P35/02C07D20060101C07D239/70C07D239/88C07D239/90C07D239/95C07D403/12C07D417/12
    • C07D403/12C07D239/70C07D239/88C07D417/12
    • Compounds of the formula (I) or salts thereof, ##STR1## wherein the dotted line represents a single or double bond, R.sup.1 is alkyl or amino optionally substituted by alkyl, alkanoyl or benzyl group: R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is selected from hydrogen, phenyl, halo, nitro, a group S(O).sub.n R.sup.8 wherein n is the integer 0, 1 or 2 and R.sup.8 is halo or alkyl or a group NR.sup.9 R.sup.10 are both hydrogen, a group NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are the same or different and each is hydrogen or alkyl, a group OR.sup.13 wherein R.sup.13 is hydrogen or C.sub.1-4 alkyl substituted by halo; a C.sub.1-4 aliphatic group optionally substituted by a group OR.sup.14 or NR.sup.14 R.sup.15 wherein R.sup.14 and R.sup.15 are the same or different and each is hydrogen or alkyl; ot two of R.sup.2 to R.sup.5 are linked together to form a benzp group, one of R.sup.2 to R.sup.3 is a group X--Y--R.sup.16 wherein X is CH.sub.2, NR.sup.17, CO, or S(O).sub.m and Y is CH.sub.2, NR.sup.17, O or S(O).sub.m, or X--Y is CH.sub.2,NR.sup.17, --CH.dbd.CH-- or --N.dbd.N--, are disclosed as pharmacological agents useful in the treatment of tumors. Pharmaceutical compositions and methods for the preparation of compounds of formula (I) are also disclosed.
    • 式(I)化合物或其盐,其中虚线表示单键或双键,R 1是任选被烷基,烷酰基或苄基取代的烷基或氨基:R 2,R 3,R 4和R 5相同或不同, 各自选自氢,苯基,卤素,硝基,基团S(O)n R 8,其中n是整数0,1或2,且R 8是卤素或烷基或基团NR 9 R 10都是氢,NR 11 R 12基团,其中R 11和R 12 相同或不同,各自为氢或烷基,OR 13基团,其中R 13为氢或被卤素取代的C 1-4烷基; 任选被OR 14或NR 14 R 15基团取代的C 1-4脂族基团,其中R 14和R 15相同或不同,各自为氢或烷基; R2至R5中的两个连接在一起形成苯并基团,R2至R3中的一个为XY-R16基团,其中X为CH 2,NR 17,CO或S(O)m,Y为CH 2,NR 17,O或 公开了S(O)m或XY为CH 2,NR 17,-CH = CH-或-N = N-作为可用于治疗肿瘤的药理学试剂。 还公开了制备式(I)化合物的药物组合物和方法。